- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04598633
Influence of Probiotics on Clinical Parameters, the Oral Microbiome and the Immune System During an Orthodontic Treatment
Influence of Probiotics on Clinical Parameters, the Oral Microbiome and the Immune System During an Orthodontic Treatment: a Prospective, Double-blind, Randomized, Clinical Study
Orthodontic treatment with fixed appliances can be necessary to correct malocclusions in adolescence or adulthood. It its known that orthodontic treatment induces aseptic pseudo-inflammatory reactions. However, studies could show that an increase of certain inflammatory cytokines during orthodontic treatment correlated with a higher risk of root resorption. Moreover, it has been shown that orthodontic treatment leads to a dysbiosis of the oral microbiome especially during the first 3 months of the orthodontic treatment. This could be a potential risk factor as the inflammation of periodontitis during an orthodontic treatment could favor root resorption and progressive destruction of the periodontal apparatus.
Probiotics are already used successfully as an adjuvant therapy in the treatment of periodontitis to improve clinical parameters and to reduce local inflammation. However, there are only a few studies that investigated the influence of probiotics during an orthodontic treatment.
Therefore, the aim of the study is to investigate if the daily intake of lozenges containing probiotics versus placebo lozenges during the first 3 months of orthodontic treatment with fixed appliances can improve clinical parameters, reduce local inflammation and prevent a dysbiosis of the oral microbiome.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Corinna Lesley Seidel, Dr.
- Phone Number: ++49-09131-85-45667
- Email: corinna.boeck@uk-erlangen.de
Study Contact Backup
- Name: Lina Gölz, Prof.Dr.
- Phone Number: ++ 49 (0)9131 85-33643
- Email: lina.goelz@uk-erlangen.de
Study Locations
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- UniversityHospitalErlangen-Nurenberg
-
Principal Investigator:
- Corinna L Seidel, Dr.
-
Contact:
- Corinna L Seidel, Dr.
- Phone Number: 091318545667 091318545667
- Email: corinna.seidel@uk-erlangen.de
-
Contact:
- Lina L Gölz, Prof.
- Phone Number: 091318545667 091318533643
- Email: lina.goelz@uk-erlangen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescents from age 12 to 17 with fixed appliances undergoing orthodontic treatment
- Signed declaration of consent by the patient and the parent or legal guardian for adolescent patients
Exclusion Criteria:
- Systemic or metabolic disease that are related to gingivitis or (e.g. diabetes) or could possibly influence the oral microbiome
obesity:
-adolescents: body mass index > + 2 standard deviations (SD) over the average value given by the World Health Organisation (weight and height will be measured)
Eating disorder or underweight
-adolescents: BMI > -2 SD under the average value given by the WHO (weight and height will be measured)
- Above-average consumption of milk products: > 3 portions/day = >1,2 liters of milk or 1200g yoghurt/day (daily dose recommended by the german society for nutrition = 1-3 portions of milk products)
- allergy to ingredients of the lozenges
- intake of antibiotics or dietary supplementation (probiotics, vitamin C/D) in the last 6 months or during the study
- regular use of antibacterial mouth wash
- pregnancy
- smoking
- retraction of the declaration of consent by the patient and the parent or legal guardian for adolescent patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Lactobacillus reuteri Prodentis®-lozenges
|
Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
|
|
Placebo Comparator: Placebo-lozenges (BioGaia)
|
Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gingival Index (GI)
Time Frame: Baseline to week 4 of intake
|
Primary endpoint is the change of the Gingival Index (GI) from baseline to week 4. The measurement of GI is described by Löe et al, which scores the gingival condition according to the defined criteria. The scores will be measured at four sites per tooth, added and divided by four to obtain the "GI for the tooth"-Index. We will use the 'GI for the tooth' described there, but only for those teeth with fixed ortodontic brackets. The 'GI for the patient' is then the mean of the GIs for the teeth. CRITERIA FOR THE GINGIVAL INDEX SYSTEM 0 = Absence of inflammation.
|
Baseline to week 4 of intake
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local cytokine expression
Time Frame: Baseline till 12 months after insertion of appliance
|
Samples from different oral niches (saliva, soft and hard tissue samples, gingival crevicular fluid) will be collected to analyse local inflammation: Unstimulated saliva will be gained by the spitting method, soft tissue samples will be collected in using sterile swabs, hard tissue samples of supragingival plaque will taken by sterile curettes and samples of gingival sulcus fluid will be collected from 6 periodontal pockets of the mesio-buccal side of defined teeth (Ramfjord teeth: 16,21,24,36,41,44) using sterile paper strips.
Sulcus fluid flow rate will be performed using Periotron 8000.
The cytokine concentration (in pg/mL) of granulocyte-macrophage colony-stimulating-factor (GM-CSF), interferon (IFN)- gamma, interleukin (IL)-2, IL-4, IL-6, IL-8 and IL-10 as well as tumor necrosis factor (TNF) in defined oral niches will be measured using multiplex immunoassay.
|
Baseline till 12 months after insertion of appliance
|
|
Oral microbiome
Time Frame: Baseline till 12 months after insertion of appliance
|
Samples from different oral niches (saliva, soft and hard tissue samples, gingival crevicular fluid) will be collected to analyse the oral microbiome: Unstimulated saliva will be gained by the spitting method, soft tissue samples will be collected in using sterile swabs, hard tissue samples of supragingival plaque will taken by sterile curettes and samples of gingival sulcus fluid will be collected from 6 periodontal pockets of the mesio-buccal side of defined teeth (Ramfjord teeth: 16,21,24,36,41,44) using sterile paper strips.
Composition of the oral microbiome will be analysed using 16 S rRNA sequencing and operational taxonomic units (OTUs) will be classified according to SILVA database.
|
Baseline till 12 months after insertion of appliance
|
|
Probing pocket depth (PPD) (4-point-measurement)
Time Frame: Baseline till 12 months after insertion of appliance
|
The measuremtn of the probing of periodontal pockets (periodontal probing depth, PPD) is performed according to standardized protocols: insertion of a perdiotonal probe into the gingival sulcus with a force of 0.2-0.3
N; probing depth is read out at landmarks on the periodontal prove.
The scores will be measured at four sites per tooth, added and divided by four to obtain the "PPDI for the tooth"-Index.
We will use the 'PPD for the tooth', but only for those teeth with fixed ortodontic brackets.
The 'PPD for the patient' is then the mean of the PPDs for the teeth.
|
Baseline till 12 months after insertion of appliance
|
|
Modified Plaque Index (MPI)
Time Frame: Baseline till 12 months after insertion of appliance
|
The measurement of Modified plaque index (MPI) is described by Attin et al, which scores the amount of plaque according to the defined criteria. The score will be measured at each tooth, but only for those teeth with fixed ortodontic brackets. The 'Modified plaque index for the patient' is then the mean of the MPIs per teeth: Index = (Sum of MPI per tooth×100)/ (3×number of measured teeth). CRITERIA FOR THE MODIFIED PLAQUE INDEX 0 = no plaque
|
Baseline till 12 months after insertion of appliance
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Baseline till 12 months after insertion of appliance.
|
Collection of adverse Events.
|
Baseline till 12 months after insertion of appliance.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Corinna Lesley Seidel, Dr., Department of Orthodontics and Orofacial Orthopedics
- Study Director: Lina Gölz, Prof.Dr., Department of Orthodontics and Orofacial Orthopedics
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ER-Ortho-Pro-RCT-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gingivitis
-
University of BelgradeActive, not recruitingPeriodontitis | Gingivitis and Periodontal DiseasesSerbia
-
State University of New York at BuffaloRecruiting
-
NovoBliss Research Pvt LtdGuruNanda LLCNot yet recruiting
-
Abant Izzet Baysal UniversityRecruitingPeriodontitis | Gingivitis and Periodontal DiseasesTurkey (Türkiye)
-
Ankara UniversityThe Scientific and Technological Research Council of TurkeyCompletedPlaque-Induced GingivitisTurkey (Türkiye)
-
Colgate PalmoliveFederal University of PelotasCompletedGingivitis | Dental Plaque | Dental Plaque Induced Gingivitis | Dental Plaque and GingivitisBrazil
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedChronic Gingivitis, Plaque InducedBangladesh
-
University of SaskatchewanCompletedChronic Gingivitis | Chronic Gingivitis, Plaque InducedCanada
-
Postgraduate Institute of Dental Sciences RohtakNot yet recruitingPregnancy GingivitisIndia
-
Zainab J AbbasCompleted
Clinical Trials on Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)
-
University of Erlangen-NürnbergBioGaia ABRecruitingGingivitis | Orthodontic Appliance Complication | Periodontal InflammationGermany
-
Malo ClinicCompletedPeri-implant MucositisPortugal
-
University of CopenhagenCompleted
-
Innovacion y Desarrollo de Estrategias en SaludBioGaia ABCompletedIrritable Bowel SyndromeChile, Mexico
-
Lama Medical Care s.r.o.BioGaia ABUnknownDyspepsia | H. Pylori InfectionSlovakia
-
University of CopenhagenCompletedPeriodontitis | Dental CariesDenmark
-
University of CopenhagenKarolinska InstitutetCompleted
-
University of CopenhagenHalmstad County HospitalUnknownPostoperative Complications
-
University of ValenciaCompleted